IL-22BP controls the progression of liver metastasis in colorectal cancer
Copyright © 2023 Giannou, Kempski, Zhang, Lücke, Shiri, Zazara, Belios, Machicote, Seeger, Agalioti, Tintelnot, Sagebiel, Tomczak, Bauditz, Bedke, Kocheise, Mercanoglu, Fard-Aghaie, Giorgakis, Lykoudis, Pikouli, Grass, Wahib, Bardenhagen, Brunswig, Heumann, Ghadban, Duprée, Tachezy, Melling, Arck, Stringa, Gentilini, Gondolesi, Nakano, Thomson, Perez, Li, Mann, Izbicki, Gagliani, Maroulis and Huber..
Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown.
Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages.
Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice.
Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 13(2023) vom: 05., Seite 1170502 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy |
|---|
| Anmerkungen: |
Date Revised 19.06.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2023.1170502 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358256097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358256097 | ||
| 003 | DE-627 | ||
| 005 | 20231226210519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2023.1170502 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358256097 | ||
| 035 | |a (NLM)37324022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Giannou, Anastasios D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-22BP controls the progression of liver metastasis in colorectal cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Giannou, Kempski, Zhang, Lücke, Shiri, Zazara, Belios, Machicote, Seeger, Agalioti, Tintelnot, Sagebiel, Tomczak, Bauditz, Bedke, Kocheise, Mercanoglu, Fard-Aghaie, Giorgakis, Lykoudis, Pikouli, Grass, Wahib, Bardenhagen, Brunswig, Heumann, Ghadban, Duprée, Tachezy, Melling, Arck, Stringa, Gentilini, Gondolesi, Nakano, Thomson, Perez, Li, Mann, Izbicki, Gagliani, Maroulis and Huber. | ||
| 520 | |a Background: The immune system plays a pivotal role in cancer progression. Interleukin 22 binding protein (IL-22BP), a natural antagonist of the cytokine interleukin 22 (IL-22) has been shown to control the progression of colorectal cancer (CRC). However, the role of IL-22BP in the process of metastasis formation remains unknown | ||
| 520 | |a Methods: We used two different murine in vivo metastasis models using the MC38 and LLC cancer cell lines and studied lung and liver metastasis formation after intracaecal or intrasplenic injection of cancer cells. Furthermore, IL22BP expression was measured in a clinical cohort of CRC patients and correlated with metastatic tumor stages | ||
| 520 | |a Results: Our data indicate that low levels of IL-22BP are associated with advanced (metastatic) tumor stages in colorectal cancer. Using two different murine in vivo models we show that IL-22BP indeed controls the progression of liver but not lung metastasis in mice | ||
| 520 | |a Conclusions: We here demonstrate a crucial role of IL-22BP in controlling metastasis progression. Thus, IL-22 might represent a future therapeutic target against the progression of metastatic CRC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a IL-22BP | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a metastasis | |
| 650 | 4 | |a tumor immunology | |
| 700 | 1 | |a Kempski, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Lücke, Jöran |e verfasserin |4 aut | |
| 700 | 1 | |a Shiri, Ahmad Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Zazara, Dimitra E |e verfasserin |4 aut | |
| 700 | 1 | |a Belios, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Machicote, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Seeger, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Agalioti, Theodora |e verfasserin |4 aut | |
| 700 | 1 | |a Tintelnot, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Sagebiel, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Tomczak, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Bauditz, Lennart |e verfasserin |4 aut | |
| 700 | 1 | |a Bedke, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Kocheise, Lorenz |e verfasserin |4 aut | |
| 700 | 1 | |a Mercanoglu, Baris |e verfasserin |4 aut | |
| 700 | 1 | |a Fard-Aghaie, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgakis, Emmanouil |e verfasserin |4 aut | |
| 700 | 1 | |a Lykoudis, Panagis M |e verfasserin |4 aut | |
| 700 | 1 | |a Pikouli, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Grass, Julia-Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Wahib, Ramez |e verfasserin |4 aut | |
| 700 | 1 | |a Bardenhagen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Brunswig, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Heumann, Asmus |e verfasserin |4 aut | |
| 700 | 1 | |a Ghadban, Tarik |e verfasserin |4 aut | |
| 700 | 1 | |a Duprée, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Tachezy, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Melling, Nathaniel |e verfasserin |4 aut | |
| 700 | 1 | |a Arck, Petra C |e verfasserin |4 aut | |
| 700 | 1 | |a Stringa, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Gentilini, Maria Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Gondolesi, Gabriel E |e verfasserin |4 aut | |
| 700 | 1 | |a Nakano, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Thomson, Angus W |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Izbicki, Jakob R |e verfasserin |4 aut | |
| 700 | 1 | |a Gagliani, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Maroulis, Ioannis C |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Samuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 13(2023) vom: 05., Seite 1170502 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:05 |g pages:1170502 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2023.1170502 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 05 |h 1170502 | ||